Cargando…

SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases

Stereotactic radiosurgery provides effective local control, but high recurrence rate are observed while ipilimumab have shown promising improvements in survival in the treatment of melanoma brain metastases. This meta-analysis was done to review the clinical evidence regarding the combination of ste...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Muhammad, Lin, Jie, Liao, Guixiang, Tian, Yunhong, Liang, Yingying, Li, Rong, Liu, Mengzhong, Yuan, Yawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137552/
https://www.ncbi.nlm.nih.gov/pubmed/30213236
http://dx.doi.org/10.1177/1533033818798792
_version_ 1783355199206719488
author Khan, Muhammad
Lin, Jie
Liao, Guixiang
Tian, Yunhong
Liang, Yingying
Li, Rong
Liu, Mengzhong
Yuan, Yawei
author_facet Khan, Muhammad
Lin, Jie
Liao, Guixiang
Tian, Yunhong
Liang, Yingying
Li, Rong
Liu, Mengzhong
Yuan, Yawei
author_sort Khan, Muhammad
collection PubMed
description Stereotactic radiosurgery provides effective local control, but high recurrence rate are observed while ipilimumab have shown promising improvements in survival in the treatment of melanoma brain metastases. This meta-analysis was done to review the clinical evidence regarding the combination of stereotactic radiosurgery and ipilimumab in the treatment of brain metastases from melanoma. Comprehensive research of the electronic databases (PubMed and Cochrane Library) was carried out in April 2017. Different combination of MESH headings and words were used. Review Manager was used to analyze the outcome data of interest. According to heterogeneity, fixed effects model or random effects model was adapted. Six retrospective studies comparing stereotactic radiosurgery plus ipilimumab with stereotactic radiosurgery alone were found. Total of 411 participants were included in this meta-analysis. Of that, 128 patients had received stereotactic radiosurgery + ipilimumab, while 283 patients had received stereotactic radiosurgery only. Stereotactic radiosurgery plus ipilimumab significantly improved survival when compared to stereotactic radiosurgery alone (hazard ratio: 0.74 [95% confidence interval: 0.56-0.99, P = .04]), with no significant increase in the incidence of adverse events (odds ratio 0.57 [95% confidence interval: 0.28-1.17, P = .12]). Stereotactic radiosurgery with ipilimumab is safe and effective treatment option and can be recommended for the treatment of brain metastases in patients with melanoma.
format Online
Article
Text
id pubmed-6137552
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61375522018-09-18 SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases Khan, Muhammad Lin, Jie Liao, Guixiang Tian, Yunhong Liang, Yingying Li, Rong Liu, Mengzhong Yuan, Yawei Technol Cancer Res Treat Review Stereotactic radiosurgery provides effective local control, but high recurrence rate are observed while ipilimumab have shown promising improvements in survival in the treatment of melanoma brain metastases. This meta-analysis was done to review the clinical evidence regarding the combination of stereotactic radiosurgery and ipilimumab in the treatment of brain metastases from melanoma. Comprehensive research of the electronic databases (PubMed and Cochrane Library) was carried out in April 2017. Different combination of MESH headings and words were used. Review Manager was used to analyze the outcome data of interest. According to heterogeneity, fixed effects model or random effects model was adapted. Six retrospective studies comparing stereotactic radiosurgery plus ipilimumab with stereotactic radiosurgery alone were found. Total of 411 participants were included in this meta-analysis. Of that, 128 patients had received stereotactic radiosurgery + ipilimumab, while 283 patients had received stereotactic radiosurgery only. Stereotactic radiosurgery plus ipilimumab significantly improved survival when compared to stereotactic radiosurgery alone (hazard ratio: 0.74 [95% confidence interval: 0.56-0.99, P = .04]), with no significant increase in the incidence of adverse events (odds ratio 0.57 [95% confidence interval: 0.28-1.17, P = .12]). Stereotactic radiosurgery with ipilimumab is safe and effective treatment option and can be recommended for the treatment of brain metastases in patients with melanoma. SAGE Publications 2018-09-13 /pmc/articles/PMC6137552/ /pubmed/30213236 http://dx.doi.org/10.1177/1533033818798792 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Khan, Muhammad
Lin, Jie
Liao, Guixiang
Tian, Yunhong
Liang, Yingying
Li, Rong
Liu, Mengzhong
Yuan, Yawei
SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases
title SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases
title_full SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases
title_fullStr SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases
title_full_unstemmed SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases
title_short SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases
title_sort srs in combination with ipilimumab: a promising new dimension for treating melanoma brain metastases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137552/
https://www.ncbi.nlm.nih.gov/pubmed/30213236
http://dx.doi.org/10.1177/1533033818798792
work_keys_str_mv AT khanmuhammad srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases
AT linjie srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases
AT liaoguixiang srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases
AT tianyunhong srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases
AT liangyingying srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases
AT lirong srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases
AT liumengzhong srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases
AT yuanyawei srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases